Understanding The Potential of SLC35B4 as A Drug Target Or Biomarker

Target Name: SLC35B4

NCBI ID: G84912

SLC35B4

Understanding The Potential of SLC35B4 as A Drug Target Or Biomarker

SLC35B4 (YEA4 homolog) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 11q34 and has been shown to encode a protein that is involved in a variety of cellular processes, including cell signaling, DNA replication, and repair.

SLC35B4 has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of SLC35B4 are associated with poor prognosis in individuals with pancreatic cancer, a type of cancer that is highly aggressive and has a high incidence of metastasis. Additionally, SLC35B4 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by progressive neurodegeneration and are some of the most common causes of dementia and Parkinson's disease.

SLC35B4 has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues and can cause significant pain and disability.

Despite the potential involvement of SLC35B4 in a variety of diseases, much more research is needed to fully understand its role and potential as a drug target or biomarker. One approach that is being explored is the use of SLC35B4 as a target for small molecule inhibitors. These inhibitors can be designed to specifically bind to SLC35B4 and prevent it from participating in cellular signaling pathways, which can be used to treat a variety of diseases.

Another approach that is being explored is the use of SLC35B4 as a biomarker for disease diagnosis and monitoring. The ability to detect and measure the expression of SLC35B4 in cells or tissues can be used to diagnose diseases at an early stage or to monitor the effectiveness of treatments. For example, the expression of SLC35B4 has been shown to be elevated in the blood of individuals with pancreatic cancer, which can be used as a biomarker for this condition.

In conclusion, SLC35B4 is a gene that has been identified as a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and potential, but the potential implications for the treatment of these conditions are significant. The development of small molecule inhibitors and the use of SLC35B4 as a biomarker for disease diagnosis and monitoring are two approaches that are being explored to fully harness the potential of this gene.

Protein Name: Solute Carrier Family 35 Member B4

Functions: Antiporter that transports nucleotide sugars across the endoplasmic reticulum (ER) membrane in exchange for another nucleotide sugar. May couple UDP-alpha-D-glucuronate (UDP-GlcA) or UDP-alpha-D-xylose (UDP-Xyl) efflux to UDP-alpha-D-glucuronate (UDP-GlcA) influx into the ER lumen, which in turn stimulates glucuronidation and excretion of endobiotics and xenobiotics

The "SLC35B4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35B4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets